EG 427 is the second company to bring a non-replicating HSV-1 vector into clinical development with an IND filling with the FDA in early 2024. Our unique platform delivers pinpoint neurotherapeutics to treat prevalent diseases of the peripheral and central nervous system. Our vectors can achieve focal transduction in specific regions and then selective expression of transgenes in targeted subsets of neurons thanks to the control of sophisticated regulatory elements. With demonstrated clinical safety and possible repeated dosing, the large payload capacity of nrHSV-1 vectors allows either for long-term gene therapy, or all-in-one gene editing approaches.